Skip to main content
Clinical Trials/NCT02391103
NCT02391103
Completed
N/A

Effects of Neuromuscular Electrical Stimulation on Muscle Mass and Strength in Critically Ill Patients After Cardiothoracic Surgery. An Ultrasound-Based Randomized Controlled Trial

Medical University of Vienna0 sites54 target enrollmentMay 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Neuromuscular Electrical Stimulation
Sponsor
Medical University of Vienna
Enrollment
54
Primary Endpoint
Muscle layer thickness (MLT)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purposes of this study are 1) to determine whether neuromuscular electrical stimulation (NMES) is effective in preventing loss of muscle mass and strength and 2) to observe the time variation of MLT and strength from preoperative day to hospital discharge.

Detailed Description

In the amendment of June 2011, a twofold study setting was defined in order to recruit patients not only before, but also after cardiothoracic surgery. In sample A, patients were recruited before surgery. In sample B, patients were recruited after surgery. On postoperative day 1, randomization was performed for sample A and B separately. To ensure balance of the NMES and control groups with respect to disease severity, randomization was stratified by the SAPS II score on the first postoperative day. In the intervention group, the anterior muscles of both thighs were electrically stimulated from the first postoperative day until ICU discharge for a maximum of 14 days. In the control group, the electrodes were applied, but no electricity was delivered.The primary outcomes muscle layer thickness (MLT) and muscle strength were assessed from the first postoperative day to ICU discharge and at hospital discharge. All patients in sample A had an additional assessment of MLT and strength before surgery. All data are analyzed according to the intention-to-treat principle with no imputation for any missing data. Linear mixed models are used to account for the repeated measurements per patient and to determine any fixed effects on MLT and MRC score.

Registry
clinicaltrials.gov
Start Date
May 2011
End Date
March 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Arabella Fischer, MD

resident

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • patients before/after cardiothoracic surgery
  • ICU stay \> 48 hours

Exclusion Criteria

  • body mass index \> 40 kg/m2
  • severe leg swelling
  • implanted ventricular assist device (RVAD, LVAD, BiVAD)
  • implanted intra-aortic balloon pump (IABP)
  • neuromuscular diseases
  • skin lesions in stimulation area
  • leg excluded if implant (hip or knee replacement) in stimulation area

Outcomes

Primary Outcomes

Muscle layer thickness (MLT)

Time Frame: on preoperative day, from postoperative day 1 onwards every other ICU day for the duration of the ICU stay (expected average of ICU stay: 7 days) and at day of hospital discharge (expected average of hospital stay: 20 days)

Muscle layer thickness of the anterior muscles of the thigh using two-dimensional B-mode ultrasound

Muscle strength

Time Frame: on preoperative day, from postoperative day 1 onwards every day for the duration of the ICU stay (expected average of ICU stay: 7 days), at day of hospital discharge (expected average of hospital stay: 20 days)

Muscle strength using Medical Research Council (MRC) score and hand dynamometry

Secondary Outcomes

  • JAGS score(on preoperative day, on day of ICU discharge (expected average of ICU stay: 7 days), on day of hospital discharge (expected average of hospital stay: 20 days))
  • FIM score(on preoperative day, on day of hospital discharge (expected average of hospital stay: 20 days))
  • SF-12 score(on preoperative day, on day of hospital discharge (expected average of hospital stay: 20 days))
  • Timed Up and Go test(on preoperative day, on day of hospital discharge (expected average of hospital stay: 20 days))

Similar Trials